• Something wrong with this record ?

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options

J. Malcikova, S. Pavlova, B. Kunt Vonkova, L. Radova, K. Plevova, J. Kotaskova, K. Pal, B. Dvorackova, M. Zenatova, J. Hynst, E. Ondrouskova, A. Panovska, Y. Brychtova, K. Zavacka, B. Tichy, N. Tom, J. Mayer, M. Doubek, S. Pospisilova

. 2021 ; 138 (25) : 2670-2685. [pub] 20211223

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22011645

Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with <10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we analyzed in a "real-world" CLL cohort. TP53 status was assessed by targeted next-generation sequencing (NGS) in 511 patients entering first-line treatment with chemo- and/or immunotherapy and 159 patients in relapse before treatment with targeted agents. Within the pretherapy cohort, 16% of patients carried low-burden TP53 mutations (0.1% to 10% VAF). Although their presence did not significantly shorten event-free survival after first-line therapy, it affected overall survival (OS). In a subgroup with TP53 mutations of 1% to 10% VAF, the impact on OS was observed only in patients with unmutated IGHV who had not received targeted therapy, as patients benefited from switching to targeted agents, regardless of initial TP53 mutational status. Analysis of the clonal evolution of low-burden TP53 mutations showed that the highest expansion rates were associated with fludarabine, cyclophosphamide, and rituximab regimen in both first- and second-line treatments (median VAF increase, 14.8× and 11.8×, respectively) in contrast to treatment with less intense treatment regimens (1.6×) and no treatment (0.8×). In the relapse cohort, 33% of patients carried low-burden TP53 mutations, which did not expand significantly upon targeted treatment (median VAF change, 1×). Sporadic cases of TP53 mutations' clonal shifts were connected with the development of resistance-associated mutations. Altogether, our data support the incorporation of low-burden TP53 variants in clinical decision making.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011645
003      
CZ-PrNML
005      
20240103104834.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2020009530 $2 doi
035    __
$a (PubMed)33945616
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malcikova, Jitka $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000336506698
245    10
$a Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options / $c J. Malcikova, S. Pavlova, B. Kunt Vonkova, L. Radova, K. Plevova, J. Kotaskova, K. Pal, B. Dvorackova, M. Zenatova, J. Hynst, E. Ondrouskova, A. Panovska, Y. Brychtova, K. Zavacka, B. Tichy, N. Tom, J. Mayer, M. Doubek, S. Pospisilova
520    9_
$a Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with 10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we $a Patients with chronic lymphocytic leukemia CLL bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy However the significance of low burden TP53 mutations with $a Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with <10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we analyzed in a "real-world" CLL cohort. TP53 status was assessed by targeted next-generation sequencing (NGS) in 511 patients entering first-line treatment with chemo- and/or immunotherapy and 159 patients in relapse before treatment with targeted agents. Within the pretherapy cohort, 16% of patients carried low-burden TP53 mutations (0.1% to 10% VAF). Although their presence did not significantly shorten event-free survival after first-line therapy, it affected overall survival (OS). In a subgroup with TP53 mutations of 1% to 10% VAF, the impact on OS was observed only in patients with unmutated IGHV who had not received targeted therapy, as patients benefited from switching to targeted agents, regardless of initial TP53 mutational status. Analysis of the clonal evolution of low-burden TP53 mutations showed that the highest expansion rates were associated with fludarabine, cyclophosphamide, and rituximab regimen in both first- and second-line treatments (median VAF increase, 14.8× and 11.8×, respectively) in contrast to treatment with less intense treatment regimens (1.6×) and no treatment (0.8×). In the relapse cohort, 33% of patients carried low-burden TP53 mutations, which did not expand significantly upon targeted treatment (median VAF change, 1×). Sporadic cases of TP53 mutations' clonal shifts were connected with the development of resistance-associated mutations. Altogether, our data support the incorporation of low-burden TP53 variants in clinical decision making.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a klonální evoluce $x účinky léků $7 D060965
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a chronická lymfatická leukemie $x genetika $x terapie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $x účinky léků $7 D009154
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kunt Vonková, Barbara $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000315289743 $7 xx0248649
700    1_
$a Radova, Lenka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000018103148X
700    1_
$a Plevova, Karla $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000261488877 $7 xx0158852
700    1_
$a Kotaskova, Jana $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000316727346
700    1_
$a Pal, Karol $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000277264691
700    1_
$a Dvorackova, Barbara $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000310858767
700    1_
$a Zenatova, Marcela $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000238556085
700    1_
$a Hynst, Jakub $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000020079845X
700    1_
$a Ondrouskova, Eva $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000308300692
700    1_
$a Panovska, Anna $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000349553039
700    1_
$a Brychtova, Yvona $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/000000031038870X
700    1_
$a Zavacka, Kristyna $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000020753051X
700    1_
$a Tichý, Boris $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000192527974 $7 xx0312236
700    1_
$a Tom, Nikola $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000174400515
700    1_
$a Mayer, Jiri $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000305679887
700    1_
$a Doubek, Michael $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000212696282
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000171362680
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 138, č. 25 (2021), s. 2670-2685
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33945616 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20240103104829 $b ABA008
999    __
$a ok $b bmc $g 1789316 $s 1162843
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 138 $c 25 $d 2670-2685 $e 20211223 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options